<DOC>
	<DOCNO>NCT02730676</DOCNO>
	<brief_summary>This study assess nicotine pharmacokinetic ( PK ) parameters adopter electronic cigarette follow 12-hour tobacco nicotine abstinence . The PK result study compare historical data smoker obtain prior study , well naïve short-term user electronic cigarette .</brief_summary>
	<brief_title>Comparison Pharmacokinetic Parameters Between Adopters Electronic Cigarettes Historical Sample Combustible Cigarette Smokers</brief_title>
	<detailed_description>This observational , open-label study assess nicotine pharmacokinetic ( PK ) parameters 6-hour period adopter electronic cigarette respect in-clinic 10-minute ad libitum period follow 12-hour tobacco nicotine abstinence . In addition PK parameter , subjective effect urge product assess 6-hour period concurrently collection PK blood sample follow protocol define schedule . The result study compare historical PK urge product data obtain smoker well naïve short-term user electronic cigarette . In addition PK parameter urge product outcome , plasma assess cotinine concentration prior 12-hour abstinence period .</detailed_description>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Menthol</mesh_term>
	<criteria>1 . Able read , understand , willing sign Informed Consent Form ( ICF ) complete questionnaire write English ; 2 . Generally healthy male female , 21 60 year age , inclusive , Screening Visit ; 3 . Breath expire carbon monoxide ( ECO ) level &lt; 10 part per million ( ppm ) Screening Visit Visit Day 1 ; 4 . Positive urine cotinine test Screening Visit Visit Day 1 ; 5 . Electronic cigarette form tobacco nicotinecontaining product use within 30 day Screening ; 6 . Willing use VUSE digital vapor cigarette study accord protocol ; 7 . Willing confine overnight abstain tobacco nicotinecontaining product use 12 hour prior investigational product use Study Discharge ; 8 . Females childbearing age must willing use form contraception acceptable Investigator time sign ICF Study Discharge , surgically sterile least 90 day prior Screening Visit ; 9 . Ability safely perform study procedure , determine Investigator ; 10 . Group 1specific inclusion criterion include follow : 1 . Currently use VUSE Original digital vapor cigarette ; 2 . Selfreports use VUSE Original digital vapor cigarette least daily , least one month prior Screening Visit . 11 . Group 2specific inclusion criterion include follow : 1 . Currently use VUSE Menthol digital vapor cigarette ; 2 . Selfreports use VUSE Menthol digital vapor cigarette least daily , least one month prior Screening Visit . 1 . Presence clinically significant unstable/uncontrolled acute chronic medical condition Screening Visit , determine Investigator , would preclude subject participate safely study ( e.g. , uncontrolled hypertension , asthma lung disease , cardiac disease , neurological disease , psychiatric disorder ) base safety assessment clinical laboratory test , medical history , physical/oral examination ; 2 . Selfreports safety labs indicate diabetes ; 3 . At risk heart disease , determine Investigator ; 4 . Use medicine treatment depression asthma ; 5 . Systolic blood pressure ≥150 mmHg diastolic blood pressure ≥95 mmHg , measure seat 5 minute ; 6 . Hemoglobin level &lt; 12 g/dL Screening Visit ; 7 . Positive test human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( antiHCV ) ; 8 . History presence hemophilia bleed disorder ; 9 . History presence clot disorder concomitant use anticoagulant ; 10 . Given whole blood donation 8 week ( ≤56 day ) prior Screening Visit ; 11 . Plasma donation within ≤7 day prior Screening Visit ; 12 . Body mass index &lt; 18.5 &gt; 40.0 kg/m2 Screening Visit ; 13 . Weight ≤110 pound ; 14 . Poor peripheral venous access ; 15 . Postponing decision quit use nicotine tobacco product ( define planning quit attempt within 30 day Screening Visit ) participate study ; 16 . Use medication substance aid smoke cessation , include limited nicotine replacement therapy ( e.g. , nicotine gum , lozenge , patch ) , varenicline ( Chantix® ) , bupropion ( Wellbutrin® , Zyban® ) , lobelia extract within 30 day prior Screening Visit ; 17 . Females test positive pregnancy , pregnant breastfeeding , plan become pregnant course study ; 18 . A positive urine drug screen without disclosure correspond concomitant medication ( ) Screening Visit Visit Day 1 ; 19 . A positive alcohol breathalyzer result Screening Visit Day 1 ; 20 . Selfreports drink 14 serving alcoholic beverage per week ( 1 serve = 12 oz . beer , 6 oz . wine , 1 oz . liquor ) ; 21 . Participation another clinical trial within 30 day prior Screening Visit , determine last visit prior trial first Screening Visit study ; 22 . Employed tobacco nicotine company , study site , handle tobacco nicotine product part job .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>electronic cigarette</keyword>
	<keyword>e-cigarette</keyword>
	<keyword>combustible cigarette</keyword>
	<keyword>cigarette</keyword>
	<keyword>menthol</keyword>
	<keyword>cig-alike</keyword>
	<keyword>subjective measure</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>crave</keyword>
</DOC>